Sophia, Advanced Humanoid
Hanson Robotics, Hong Kong
The future is here and her name is Sophia, the world’s very first humanoid celebrity. The toast of the Tonight Show with Jimmy Fallon, Sophia has graced the cover of Elle magazine, appeared on Chinese television, spoken before the United Nations General Assembly and named the first non-human citizen of Saudi Arabia. Wowing awestruck audiences with her superhuman intelligence and advanced ability to read faces, empathize with emotions, understand the nuances of language and communicate with thousands of facial expressions, Sophia has discussed subjects ranging from “Will robots take over the world?” to how artificial intelligence could end hunger in developing nations. Sophia interacts with humans in a profoundly personal way, previewing a fast-approaching future where friendly, caring humanoids help us solve our most challenging problems to create a better world.
From Hong Kong to the U.S., Europe and Australia, Sophia has sung in concert, addressed audiences in Mandarin, debated the future of the human race (against another robot), and generated billions of views and social media interactions. She has also displayed her expansive tech knowledge and growing business savvy, meeting with leaders in the banking, insurance, automotive, property development, media and entertainment industries. A versatile and ingenious presenter who customizes her appearances with encyclopedic event-specific content, Sophia has appeared as a panel-member and speaker at high-level conferences, addressing how robotics and artificial intelligence will become an integral part of everyone’s everyday lives and work.
Sophia is the brain child of Dr. David Hanson of Hong Kong-based Hanson Robotics, a modern-day renaissance man who has built a reputation for creating the world’s most humanlike robots. A former Disney Imagineer, Dr. Hanson’s mission is to create genius machines that are smarter than humans and able to learn creativity, empathy and compassion.
Appearing alongside Dr. Hanson or on her own, Sophia enchants audiences with a captivating, interactive look at the awe-inspiring potential of AI and robotics. She also provides enlightening insights into the provocative moral and ethical questions that accompany non-human intelligent lifeforms. As both the state-of-the art in technology and the state-of-the-heart in human-humanoid relations, Sophia always draws a crowd and brings a unique and unforgettable experience to any event.
Boston University, USA
Rhoda Au is Professor of Anatomy & Neurobiology, Neurology and Epidemiology at Boston University Schools of Medicine and Public. She also currently serves as Director of Neuropsychology at the Framingham Heart Study, where she has been involved in research related to cognitive aging and dementia since 1990. Most recently, she has been exploring the potential of cognitive digital biomarkers and how “big data” analytics can better inform our understanding of Alzheimer’s disease pathways and treatment. Beyond Framingham, Dr. Au is focused on building multi-sector ecosystems to enable solutions for chronic disease prevention generally and optimizing brain health specifically and to move the primary focus of health technologies from precision medicine to a broader emphasis on precision health.
Actress, activist on Traumatic Brain Injury; WBP Ambassador, USA
Chéri Ballinger is a professional actress, fashion model, and movie producer who has appeared in numerous films, TV shows, and commercials and print advertisements worldwide. She got her start in film while being discovered as a young girl and placed in the iconic Disney film “The Parent Trap” in 1998. She has worked in film steadily ever since. For nearly ten years, she was the official spokesmodel of Sun Labs/Giselle Cosmetics, representing them in all global media and events. Her dedication, optimism, and strong work ethic allowed her to earn a Bachelor’s Degree from California State University while simultaneously working around the world. In 2014, Chéri suffered from a horrific accident that left her with a severe traumatic brain injury (TBI). After years of grueling physical and speech therapy, as well as the grim prospect that she would not be able to have a full life again, Chéri overcame all the odds against her. With her passion for her second chance at life and her effervescent personality, she is now back to work in Hollywood primarily producing movies while also focusing on her international philanthropy efforts. Her latest feature film is the much anticipated “Roe v Wade” to be released in mid-2019. While currently working on a number of other incredible films, she’s also now producing an exciting feature entitled “Lazarus”. Chéri is focused on producing films that bring both entertainment and positive messages to an international audience. In addition, she is now an international speaker and the official ambassador for the Women’s Brain Project based in Switzerland.
Beatrice Beck Schimmer
Director of the Medical University of Zurich, Switzerland
Prof. Dr Beatrice Beck Schimmer is full professor of anesthesiology at the University of Zürich (UZH). Currently she is Vice President Medicine at the UZH and in charge of the leadership and management of the Faculty of Medicine together with the dean and deputy dean. She is responsible for the strategic development of academic medicine at UZH in cooperation with the ETH Zurich and the four University hospitals.
Previously, she held the role of Vice Dean for Academic Career Development and Equal Opportunities at the Faculty of Medicine of the UZH.
She studied human medicine at the University of Bern and gained her habilitation at the University of Zurich in 2003. From 2005 to 2018, she was Chief of Service at the Department of Anesthesiology at the University Hospital Zurich. She has been a full professor of anesthesiology since 2009.
Director of Research, Lurie Center for Autism Mass General Hospital for Children, Boston, USA
Dr. Staci Bilbo is the Lurie Family Associate Professor of Pediatrics and Neuroscience at Harvard Medical School and the Director of Research for the Lurie Center for Autism at Massachusetts General Hospital for Children. Her research is broadly focused on the mechanisms by which the immune and endocrine systems interact with the brain to impact health and behavior. Current research in her laboratory focuses on understanding the consequences of early life events, including infection, stress, environmental toxins, and maternal obesity on neural and immune system development, with an emphasis on sexually-dimorphic disorders such as autism spectrum disorder. A particular focus of the work is on the resident immune cells of the brain, microglia, including sex differences in their development and function, and in response to early life inflammatory signals.
Medical Director, Barcelona Alzheimer Treatment & Research Center, Spain
Neurologist (Universitat de Barcelona,1972). PhD in 1993. Founder and medical director of Fundació ACE 1995. Distinguish professor of Universitat Internacional de Catalunya. Former President of the Catalan Society of Neurology (2000-2002).
Research Interest: Alzheimer’s disease and related dementias, including diagnosis, pharmacologic and non-pharmacologic treatment and basic, social, bioethical and legal research applied to the welfare and protection of people suffering dementia and their caregivers.
From 1996 to 2001, advisor on the bioethics committee of the Catalan Government, technical coordinator for the design of care model for people with cognitive impairment, and President of the committee for the Pharmacological Treatment for Alzheimer’s disease of the Catalan Government (CATMA).
Co-director Documento Sitges 1st and 2nd edition.
Member of the Executive Committee of the European Alzheimer’s Disease Consortium (EADC) and Member of European Institute of Womens Health (EIWH) Advisory Board.
Leader of several projects funded by the Spanish and Catalan Governments, European Union and private institutions: AES, H2020, EFSD, ERA-NET, IMI2, Fundació La Caixa, and Grifols.
To date, leader of more than 110 clinical trials as well as authorship of more than 220 articles, 36 book chapters and 12 books of medical outreach.
Among other awards, recipient of the Professional Excellence Award by the Medical Council of Catalonia (2008); the Josep Trueta Medal for Health Merit, from the Generalitat de Catalunya (2012); the highest honor conferred by the Catalan Government, the “CreudeSantJordi” (St.George’sCross) for her work in the field of Alzheimer’s disease (2014), and Honorable Member of the Spanish Society of Neurology.
DayOne Basel, Switzerland
University of Arizona, USA
Dr. Roberta Diaz Brinton leads the Center for Innovation in Brain Science at the University of Arizona whose mission addresses neurodegenerative diseases of aging, Alzheimer’s, Multiple Sclerosis, Parkinson’s and ALS.
Brinton is an internationally recognized expert in the systems biology of Alzheimer’s disease and is developing the first regenerative therapeutic to regenerate the degenerated brain. Her analyses focused on the brain at greatest risk for Alzheimer’s, the aging female brain. Brinton’s research has shown that the aging brain undergoes a set of sequential bioenergetic and neuro-immune transitions that can lead to neurodegenerative disease. Further, her findings show that the sex difference in Alzheimer’s disease is not because women live longer than men, as commonly thought, but rather because the disease starts earlier in the female brain. Her insights into the transition states of the aging brain provide therapeutic opportunities to prevent, delay and treat neurodegenerative disease.
Brinton earned her Ph.D. as an NIH Predoctoral Fellow at the University of Arizona and went on to Rockefeller University as an NIH Postdoctoral Fellow. Subsequently, Brinton joined the University of Southern California faculty where she was Professor of Molecular Pharmacology, Biomedical Engineering and Neurology. Currently, Brinton is Professor of Pharmacology, Neuroscience and Neurology at the University of Arizona College of Medicine and Director of the Center for Innovation in Brain Science. She serves on the Alzheimer’s Drug Discovery Foundation Board of Governors and has serves on National Institute of Health scientific advisory boards and review panels. Her research has been continuously funded by the National Institutes of Health and for over two decades by the National Institute on Aging.
Brinton’s scientific research and STEM education endeavors have been recognized by numerous awards including Scientist of the Year by the Alzheimer’s Drug Development Foundation, Goodes Prize for Excellence in Alzheimer’s Drug Discovery, National Institute of Aging MERIT Award, the US Presidential Citizens Medal in 2010 and Ten Best Minds by US News and World Report.
University of Zurich, Switzerland
Thorsten Buch is director of the Insitute of Laboratory Animal Science at the Vetsuisse Faculty of the University of Zurich
The institute is the largest provider of the legally required courses for animal experimentators in Switzerland, with a new set of courses targeted towards reproducibility and quality of science.
Also in his curricular teaching he is enaging strongly in the topic of animal ethics and experimental design.
Thorsten Buch has been working since 1994 on immunological tolerance, with a strong neuroimmunological focus. The research projects in his institute are frequently interdisciplinary and geared towards bridging the whole spectrum from basic reasearch to actual translation in a spin-off.
Thorsten Buch is member of the Commission for Sex and Gender in Medicine at the University of Zurich.
International Corporate Affairs Pain Platform and Alzheimer’s disease Eli Lylli Global, USA
Laura Campo is responsible for the out-of-US relationships with Patient Associations and Health Professionals in the Global Corporate Affairs division at Eli Lilly and Company. In her role, Laura coordinates Lilly’s efforts to engage the external environment in Alzheimer’s disease, Migraine and Pain.
Before joining the International Corporate Affairs role, Laura served as Corporate Affairs Market Access Manager at Eli Lilly Italia, supporting the Regional access plans in the Oncology, Cardiovascular, CNS, and other therapeutic areas, with a special focus on the partnership programs with Regional Institutions on the optimization of NHS processes.
During the years in the Italian Corporate Affairs Division, Laura also covered the role of Country Leader for two major Lilly efforts in the environment engagement space, raising the attention to public policy issues that limit the access to patient’s care in the Oncology area and in the Alzheimer’s disease area.
In the previous years within Eli Lilly and Company, Laura covered other National and International roles as Marketing Manager in the Attention Deficit & Hyperactivity Disorder area in Lilly Italia, European Regulatory Affairs Manager in the UK and Research Scientist in the Lilly Research Laboratories (Indianapolis).
Laura pursued a post-doctoral fellowship at the University of Alabama at Birmingham and her graduate school in Italy where she currently lives.
Founder and CEO of Forestay River Consulting Ldt, Switzerland
Tania Dussey-Cavassini combines nearly 30 years of hands on experience in global health, diplomacy, business consulting, executive education and law enforcement with strong exposure to companies ranging from global services, life sciences, consumer products to heavy industries. As Ambassador for Global Health and Vice-Director General of the Swiss Federal Office of Public Health, in charge of International Affairs (2013-2017), Tania advocated for the transfer of ideas and best practices to enhance the Swiss Health System. Tania is a Harvard Fellow (2012-2013). She was educated in management at IMD, in law at the University of Lausanne, and music at the University of Music Lausanne. She is a certified coach with The Actor’s Institute, New York. Tania serves on the Board of Directors of the Here-Geneva Foundation (Humanitarian Exchange and Research Centre). She is member of the Advisory Board of The Women’s Brain Project, promoting gender-based research. She is the founder and CEO of Forestay River Consulting Ldt.
Geoffrey Beene Foundation Alzheimer’s initiative, USA
Meryl Comer is a co-founder of Women Against Alzheimer’s/USA2 Network and a founding partner of The Global Alliance on Women’s Brain Health. For more than a decade (2007- 2019), Ms. Comer served as President and CEO of the Geoffrey Beene Foundation Alzheimer’s Initiative, a catalyst funder with a vision toward the future, targeting AD prevention through spirited public engagement campaigns, early assessment technologies, support of the first “virtual registry” as a power pool for big data, champion of AD patient and caregivers, and pre-clinical AD research to modify disease risk. She serves on the NIH National Advisory Council on Aging (NACA).
Vice-President of the European Stroke Organization, University of Lille, France
Prof. Charlotte Cordonnier, MD, PhD, is a neurologist specialised in stroke medicine. Appointed as Professor of Neurology at the Lille University (France) in 2012, she is the head of the department of Neurology & Stroke centre of the Lille University Hospital. Her research interests are intracerebral haemorrhages (including microbleeds) both in the setting of stroke and dementia, acute management of stroke, and stroke specificities in women. She is the director of the Lille Haemorrhagic Stroke research program inside the INSERM U1171. She has been a member of the Institut Universitaire de France since 2015, and serves as vice-president of the European Stroke Organisation (2016-2020). She is one of the founding members of the Women Initiative for Stroke in Europe (WISE).
Reader in Forensic & Neurodevelopmental Psychiatry, UK
Dr Craig completed a dual training in Psychiatry (FRCPsych) and Obstetrics & Gynaecology (FRCOG). He was subsequently awarded an MRC(UK) Clinical Training Fellowship to complete a PhD into the effects of sex hormones on the brain using in vivo brain imaging. His research and clinical interests remain focused on translational aspects of reproductive and neurodevelopmental psychiatry. He is Director of the National Female Hormone Clinic at the Maudsley Hospital and Reader in Neurodevelopmental Psychiatry at the IoPPN, Kings College London.
Co-Founder, Ellpha Project, USA
Stephanie is the CEO and co-founder of Ellpha, the first Artificial Intelligence program designed to detect and help fight gender bias in content, systems or processes.
She trained as an Aeronautics engineer in Ecole Centrale Paris and has always had a passion for science, data and technology. After working in the Aeronautics industry, she spent 20 years in the fmcg industry leading global strategic insights teams and understanding the consumers psychology and behaviours behind market growth.
The science around unconscious bias resonates with Stephanie’s own life experience as a daughter, sister, mother and passionate manager & mentor of women in the workplace.
In 2017 this instilled her drive to use data and AI to accelerate reaching gender parity and co-found the ellpha project.
Winner of the THE ONE International Humanitarian Award, Founder of The Mauli House, India
He is from India. Education: M. D. (Homoeopathy), M. A. (Clinical Psychology), PGDEMS (Post graduate diploma in emergency medical services), NTMC (National trauma management course)
Name of Organization: Mauli Seva Pratishthan (MAULI HOUSE), Designation- Chief Functionary / President
Work: Working for wondering, homeless mentally ill women and their children found on road. Providing Lifelong care and home. Taking care of pregnant women who are abused mentally and physically. Conducting labor of such homeless, destitute pregnant women and taking lifelong care of them and their children. Currently there are 160 women and 21 children which are born in MAULI. Taking care of destitute women having dreadful diseases and critical illnesses, such as tuberculosis, HIV AIDS, venereal diseases, cardiac and metabolic diseases. Running and managing first of its kind intensive care unit for homeless, destitute women who are abandon by their families on road to die. Construction of 600 bed MANGAV project phase first is completed now with inmate capacity of 120 women. Total 500 homeless mentally and physically ill women will get lifelong home and 100 bed super specialty hospital for critically ill and dying who are found on road. He is also founder and President of NNG INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES INDIA. This institute is an autonomous institute and one of its kind dedicated for research and development in the field of mental health and neurosciences in India. He is Writer and filmmaker made many documentaries and films on social issues. Many documentaries made by him showcased in well-known International film festivals around the globe.
Duke University, USA
Dr. Murali Doraiswamy is a physician-scientist at Duke University where his research focuses on precision medicine and digital health. He also serves as an advisor to leading government agencies, businesses and advocacy groups. He is a member of the World Economic Forum’s Global Future Councils and co-author of a popular book, The Alzheimer’s Action Plan.
Author of the book “Doing Harm”, USA
Maya Dusenbery is an American journalist and author of the book Doing Harm: The Truth About How Bad Medicine and Lazy Science Leave Women Dismissed, Misdiagnosed, and Sick. She is editorial director of the award-winning site Feministing.com and was formerly a fellow at Mother Jones magazine and a columnist at Pacific Standard. Her writing has appeared at Slate, The Atlantic, HuffPost, Cosmopolitan, Popular Science, and more. Before becoming a full-time writer, she worked at the National Institute for Reproductive Health. A Minnesota native, she is currently based in Portland, Oregon.
Senior vice President of Neuroscience-20, Verticai Consulting and Ventures, Switzerland
Christoph Ebell is an entrepreneur, science diplomat, technology consultant and transformation strategist. He was born in Bern in 1972. He first studied physics, then humanities and graduated in Bern and Chicago. After a research stay in Cambridge (USA), he worked for the Swiss government’s innovation agency CTI, then for the Swiss Interior, Economy, and Foreign Affairs Departments and was transferred to head the Science Section at the Swiss Embassy in Washington, D.C. Back in Switzerland, he worked for the Human Brain Project, a multidisciplinary EU project in computer-based brain research and the largest of its kind in Europe, for the last 3 years as its Executive Director. In 2018 Chris Ebell established a consulting firm for technology projects and venture capital, and is mandated as COO of a German software company for next generation High Performance Computing. He speaks frequently at international events. He is based in Geneva, Switzerland.
Maria Teresa Ferretti
Chief Scientific Officer, WBP, Switzerland
After growing up in Sardinia (Italy) my studies led me to Spain, England, Canada and finally Switzerland.
Here I am currently a junior group leader at University of Zurich working on biomedical research in the field of Alzheimer’s disease.
My goals are to help finding a cure for this devastating disease and to support the lives of Alzheimer’s patients and caregivers. It was shocking to learn that both are overwhelmingly women. Therefore I enthusiastically joined the Women’s Brain Project organization as a vehicle to promote gender-related science and advocate for actions in support of caregivers.
University of British Columbia, Canada
Liisa Galea is a Professor in the Department of Psychology, a member of the Centre for Brain Health, Director of the Graduate Program in Neuroscience, and a Scientific Advisor at Women’s Health Research Institute at the University of British Columbia. My research investigates how sex hormones influence brain health and disease in both females and males. The main goal of my research is to improve brain health for women and men by examining the influence of sex and sex hormones on normal and diseased brain states such as depression and Alzheimer’s disease.
Harvard School of Medicine, USA
Nouchine Hadjikhani, MD, PhD, is Associate Professor in Radiology at Harvard Medical School, where she directs the Neurolimbic Research Laboratory. She is also an Assistant in Neurosciences at the Massachusetts General Hospital and Visiting Professor at GNC, Gothenburg University, Sweden. She is an author of 105 peer-review articles and 14 books, book chapters and other publications.
She has been doing brain imaging for more than twenty years, using neuroanatomy, histology, Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), magnetoencephalography (MEG) as well as behavioral methods, including eye-tracking, to study the normal and the diseased brain. Her research stems from her interest of the visual system and include conditions such as migraine and autism.
Commissioner for Women’s Health FDA, USA
Parteners MS Center Brigham and Women’s Hospital Harvard Medical School, USA
Dr. Maria Houtchens is an Associate Professor at Harvard Medical School in Boston, MA. Dr. Houtchens received her M.D. degree from the University of Utah School of Medicine and completed her neurology residency at Harvard. She also received a Masters of Medical Sciences degree from Massachusetts Institute of Technology/Harvard School of Public Health. She finished a fellowship in Multiple Sclerosis and Demyelinating Diseases at Partners Multiple Sclerosis Center, Brigham and Women’s Hospital (Dr. Howard Weiner) and established herself as an independent clinical researcher and an expert in the field of Women’s Neurology as it relates to MS patients. She is a neurologist at the Brigham and Women’s Hospital, and a Director of Women’s Health Program at Ann Romney Center for Neurologic Diseases/Partners MS Center. She is well known nationally and internationally for her work in women’s health, and has published numerous research and review articles on subject of pregnancy management and women’s health in multiple sclerosis, as well as trained numerous residents and fellows in this field. Her current research focus is on establishing MS disease-state pregnancy registries, understanding the incidence and prevalence of depression and inflammation correlates in post-partum MS patients, and assuring equitable and equal access to care for MS patients regardless of gender.
Institute for Ethics and Emerging Technologies, Trinity College in Hartford, Connecticut, USA
James Hughes Ph.D. is a bioethicist and sociologist who serves as the Associate Provost for the University of Massachusetts Boston (UMB), and as Senior Research Fellow at UMB’s Center for Applied Ethics. He holds a doctorate in Sociology from the University of Chicago where he taught bioethics at the MacLean Center for Clinical Medical Ethics. Since then Dr. Hughes has taught health policy, bioethics, medical sociology and research methods at Northwestern University, the University of Connecticut, and Trinity College. Dr. Hughes is author of Citizen Cyborg: Why Democratic Societies Must Respond to the Redesigned Human of the Future (2004) and is co-editor of Surviving the Machine Age: Intelligent Technology and the Transformation of Human Work (2017). In 2005 Dr. Hughes co-founded the Institute for Ethics and Emerging Technologies (IEET) with Oxford philosopher Nick Bostrom, and since then has served as its Executive Director. Dr. Hughes serves as Associate Editor of the Journal of Evolution and Technology, and as co-founder of the Journal of Posthuman Studies. Dr. Hughes speaks on medical ethics, health care policy and future studies worldwide.
Singularity University, Switzerland
Head of Strategy and Future Media at the European Broadcasting Union until November 2014, she earned a Ph.D (summa cum laude) in 2015, focusing on Ethics and Emerging Technologies.
Member of the International Academy of Television Arts and Sciences, she’s a BAFTA guru and a Senior Advisor at Singularity University.
International speaker and event moderator, she has curated five editions of TEDxTransmedia and nine European Broadcasting Union Summits.
On December 2017 she will curate and host the first edition of TEDxCarouge.
Currently, she studies the future, she works on ethics and emerging technologies, she teaches “Emerging Media” at Webster University Geneva and is visiting professor, at Jinan University, in Guangzhou, China, teaching Virtual reality storytelling and VR journalism.
I have investigated and written on the topic of ethics and exponentially growing technologies in both my Ph.D. thesis and in my ongoing book, entitled Exponential Ethics.
Here’s an article I wrote on the subject.
Ethics must keep up with the exponential progress of technology; it must leapfrog and facilitate public debates among influential contemporary thinkers, scientists, artists, engineers, philosophers, and science-
This will be the most pioneering decade in history.Exponential technologies will lead to exponential innovation.
We should strive to take this journey, conscious of the risks we are facing, and raise a call to action for openly discussing the social repercussions these technologies could have if left only to their “makers”—a call to action to “Reboot Ethics.”
Executive Director Mary Horrigan Connors Center for Women’s Health and Gender Biology, Vice Chair for Research, Department of Psychiatry Brigham and Women’s Hospital, USA
Dr. Joffe is the Paula A. Johnson Associate Professor of Psychiatry in the Field of Women’s Health at Harvard Medical School, Executive Director of the Connors Center for Women’s Health and Gender Biology at Brigham & Women’s Hospital, and Director of the Women’s Hormones and Aging Research Program. Dr. Joffe is an experienced clinician and clinical reproductive neuroscientist in women’s aging and mental health. Her work focuses on the mechanisms, course, and treatment of menopausal symptoms (hot flashes, insomnia, depression, fatigue) in healthy women and breast cancer survivors. For 20 years, she has been funded by the NIH and pharmaceutical companies. The Connors Center goal is to ignite change in sex/gender medicine, including through their First-in-Women Precision Medicine Platform.
CNN Money Switzerland
Amanda Kayne is a news anchor at CNNMoney Switzerland. In 2011 she joined Julius Baer as the communications face of the bank and to lead its global future trends initiative. Previously, the British native was a journalist for the BBC’s World Business report and a reporter for CNBC Europe. She began her career as a current affairs presenter for the news network Russia Today. She holds postgraduate diplomas in economics from the London School of Economics and in print journalism from the National Council for the training of Journalists UK.
Wyss Research Center, Switzerland
Director, Interactive Robots and Media Lab MIT, USA
Nikolaos Mavridis, PhD from the Massachusetts Institute of Technology (MIT), is an Academic and Consultant specializing in Robotics and Artificial Intelligence. He is the founder and director of the Interactive Robots and Media Lab (IRML), and has served as faculty at numerous institutions, including New York University (NYU) AD, the National Center for Scientific Research Demokritos, and others. His interests include intelligent robots, and especially verbal and non-verbal communication with robots, artificial intelligence, machine learning, and cognitive systems. He has served in numerous leadership and pro-bono positions, has been a TEDx Speaker four times, including Geneva and Athens, and is a member of the MIT Education Council and a mentor for the MIT Enterprise Forum.
Associate Director Alzheimer’s Prevention Clinic of Weill Cornell Medical College (WCMC), USA
Dr. Lisa Mosconi, PhD, is Associate Professor of Neuroscience in Neurology at Weill Cornell Medical College (WCMC)/NewYork-Presbyterian Hospital, where she serves as Director of the Women’s Brain Initiative (WBI) research program and Associate Director of the WCMC Alzheimer’s Prevention Clinic. She also is an adjunct faculty member at the Department of Psychiatry at NYU School of Medicine, and at the Department of Nutrition at NYU Steinhardt School of Nutrition and Public Health. Dr. Mosconi is well known for her research on the early detection of Alzheimer’s disease in at-risk individuals, women in particular, using brain imaging techniques such as PET and MRI.
Associate Professor of Psychiatry Director, Women’s Mood Disorders Center Johns Hopkins School of Medicine, USA
Dr. Payne is an Associate Professor of Psychiatry and the Director of the Johns Hopkins Women’s Mood Disorders Center. She received her medical degree from Washington University, completed her residency in psychiatry at Johns Hopkins and finished a fellowship in mood disorders through the Mood and Anxiety Disorders Program at NIH. In addition to providing outstanding clinical care for women with mood disorders, Dr. Payne conducts research into the genetic, biological, and environmental factors involved in postpartum depression and studies best practices for the management of mood disorders during and after pregnancy. She and her colleagues have recently identified two epigenetic biomarkers of postpartum depression and are working hard to replicate this work with NIH funding.
National Institute on Aging – Program director in the Division of Neuroscience, USADr. Petanceska is a Senior Advisor for strategic development and partnerships and a Program Director for systems biology and systems pharmacology in the Division of Neuroscience at the National Institute on Aging (NIA). She was instrumental for the development of NIA’s Alzheimer’s Disease (AD) Translational Research Program and leads NIA’s open-science, systems biology programs for target and biomarker discovery: the AMP-AD Target Discovery and Preclinical Validation Project and the M2OVE-AD and Resilience-AD Consortia. She also leads the Institute’s funding initiative focused on applying, integrative, data-driven approaches to understand the impact of sex differences on the molecular mechanisms underlying AD risk and responsiveness to treatment.
a patient living with Alzheimer’s disease & WBP Ambassador, Sweden
I am a woman of 43 years, who has been impacted by Alzheimer’s Disease for more than half of my life. My grandmother was buried during my first year and the autopsy showed Alzheimer’s. When I was 14 my father was affected by the disease and eventually died in 1999. His seven years younger brother died seven years after in the same disease.
I am thus committed to educate people about the Alzheimer’s Disease. With money from the Swedish Alzheimer Association I was able together with two other persons to make a film about being young and related to this disease.
I could not have imagined that seventeen years after my father’s death, I would receive the news that I was affected as well! l At the age of 39.
Unfortunately, I had to struggle at first to believed by doctors. When I passed most of the standardized tests, the doctors said that it was nothing to be worried about. I had to change doctors twice! But I finally got the help, when I got in contact with my father’s old retired doctor.. While the medical investigation was going on, I studied to be a health educator and managed a three-year education at the university.
My goal is to write about the many challenges of young-onset Alzheimer’s patients, and especially women’s encounters.
Read my stories @ “Sofia’s Corner”
University Hospital Barcelona, Spain
Patricia Pozo-Rosich MD PhD, is a specialist in Neurology. She is in charge of the Headache and Craniofacial Pain Clinical Unit at the University Hospital Vall d’Hebron in Barcelona, Spain; and the Headache Research Laboratory at the Vall d’Hebron Institute of Research (VHIR), which belongs to the Universitat Autonoma of Barcelona (UAB).
After winning the la Caixa, American Headache Society, Rio Hortega, EFNS, research awards she became a Fellow in Preclinical Research with Professor Silberstein at the Thomas Jefferson University in Philadelphia (PA, USA) and later on with Professor Goadsby both at Queen’s Square – University College London (UK)– and at the University of California at San Francisco (CA, USA).
She is the Coordinator of the Spanish Headache Study Group of the Spanish Neurological Society (cefaleas.sen.es), she is a member of the International Headache Society Board of Trustees, the International Headache Society Clinical Trials Guidelines Committee and the European Headache Federation Council.
She is the Editor for Headache for Revista de Neurologia, an Associate Editor of Frontiers in Neurology (Headache Medicine) and a member of the Editorial Advisory Board of The Journal of Headache and Pain.
Dr. Pozo-Rosich’s research focuses on better understanding the pathophysiology of migraine from a multidisciplinary approach using genetics, neuroimaging and electrophysiology. She has developed the Migraine Adaptive Brain research program. In this regard, she is a member of the International Headache Genetics Consortium. She has been awarded research grants from the la Caixa Foundation, Fondo de Investigaciones Sanitarias (ISCIII), la Marató TV3 Foundation, AGAUR, Mutual Medica and, the Migraine Research Foundation.
She has been the principal investigator of clinical trials in phases II and III.
She educates neurologists, other physicians and patients with the goal of improving the quality of life of patients suffering from headache and helping reduce the stigma of migraine. She is the founder and developer of the website in Spanish dedicated to headache www.midolordecabeza.org for patients and physicians which has more than 5,800 registered users and more than 25,000 facebook followers.
University of Zurich, Switzerland
Dr. med. Katrin Rauen is Fellow of the European Board of Neurology, consultant in Neurology and Psychiatry at the Department of Geriatric Psychiatry, University Hospital of Psychiatry Zurich “Burghölzli”, scientifically specializing on the neuroinflammatory and neurodegenerative long-term sequels following Traumatic Brain Injury (TBI). Dr. Rauen is holding a dual affiliation as Principal Investigator to the Institute of Regenerative Medicine at the University of Zurich (IREM), Switzerland, as well as to the Institute of Stroke and Dementia Research (ISD) at the Ludwig-Maximilians-University, Munich, Germany.
The overarching goal of Dr. Rauen´s research is to elucidate the pathophysiology of chronic TBI and to elucidate biomarkers to better stratify patients being at risk for posttraumatic cognitive decline, thereby setting the basis for new anti-inflammatory and anti-dementia therapy. Furthermore, she aims to implement neuro-psychiatric diagnostic algorithm to early identify patients being at risk for psychiatric disorders to support patients and their caregivers to adapt to the posttraumatic condition and to regain best quality of life despite the lifechanging brain trauma.
Dr. Rauen received her M.D. in 2011 from Ludwig-Maximilians-University, Munich, Germany and gained international experience at the UCL Queens Square Institute of Neurology, London, England, at Kaiser Permanente Rehab Center, Vallejo, California, USA, and at the University of Stellenbosch, South Africa. Her doctoral thesis Influence of vasopressin receptors and aquaporins on secondary brain injury following experimental TBI at Professor Plesnila´s laboratory at LMU Munich was honored summa cum laude in 2014. Dr. Rauen received honors and awards from the German Society of Neurology, German Society of Neurosurgery, International Neurotrauma Society, German Society of Neuroscience, European Academy of Neurology and European Brain Injury Consortium (EBIC). She is part of the ERA-Net Neuron CnsAflame TBI consortium on neuroinflammatory mechanisms following TBI and executive board member of the Women´s Brain Project to elucidate sex and gender differences following TBI.
University of Lucern, Switzerland
Sara is Assistant Professor of Health Communication at the Department of Health Sciences and Health Policy of the University of Lucerne (CH), and Leader of the Person-Centered/Health Communication Group at Swiss Paraplegic Research (CH). She is currently the President of the International Association for Communication in Healthcare (EACH), and scientific consultant for the World Health Organization. Her background is in philosophy, rhetoric, argumentation theory and persuasion research, theories and models of communication, information and education, human empowerment and critical thinking, with a specific focus on healthcare and qualitative research.
Antonella Santuccione Chadha
CEO, WBP; Roche Diagnostic, Switzerland
Dr. Antonella Santuccione Chadha is a medical doctor with profound expertise in clinical pathology, neuroscience and psychiatric disorders. Currently she works as an Global Medical Manager for Alzheimer’s disease at Roche Diagnostic. She is a co-founder and CEO of the non-profit organization “Women’s Brain Project” which is addressing the influence of sex and gender on mental disorders and novel technologies. As a medical doctor, Antonella has decades of experience in preclinical research, patient treatment, clinical development, and setting up the international regulatory framework for Alzheimer’s disease. Always focused on solving the puzzles related to Alzheimers and other psychiatric diseases, she has worked with Swissmedic, the Bill and Melinda Gates Foundation, several European universities, the EU commission for Health and Food Safety, the World Health Organization and several Alzheimer’s’ disease Organizations. Antonella has been nominated in 2018 among the TOP 100 Women in Business in Switzerland and in 2019 as the most prominent people in the city of Basel. Antonella Santuccione Chadha is keenly interested in removing bias so that precision medicines and novel technologies can be delivered to patients in a more precise and timely manner. She is advocating and acting for the creation of an Institute for sex and gender precision medicine in Switzerland.
Annemarie Schumacher Dimech
President, WBP, Switzerland
Annemarie serves as President of the Women’s Brain Project and she is a founder of the Women’s Brain Project. Her strong interest in mental health issues started in Malta where she read for a Bachelor’s degree in psychology. Later she studied health psychology at the University of Surrey (UK) and after that she spent a couple of years working with children with mental and/or physical disability. Annemarie Switzerland in 2005 and read for a PhD at the University of Bern. Annemarie worked as a researcher and teacher in the area of health and exercise psychology.
Silvina Catuara Solarz
Silvina Catuara Solarz, Telefonica Innovation Alpha, Spain
Silvina Catuara Solarz is the Strategy Manager at the Health Moonshot at Telefonica Innovation Alpha. She holds a PhD in Translational Neuroscience from the Pompeu Fabra University that she developed at the Centre for Genomic Regulation (CRG) and the Hospital del Mar Research Institute (IMIM), Barcelona, Spain, in 2016. She has experience in experimental and clinical research on neurodevelopmental and neurodegenerative disorders using digital assessment and interventions.
Her main interests include the application of digital technologies and artificial intelligence to prevent and manage mental and physical conditions.
Health Policy Analyst at OECD, France
Elina Suzuki is a policy analyst in the Health Division at the Organisation for Economic Co-operation and Development (OECD). Her work focuses on projects related to dementia, ageing, long-term care, and the use of new digital tools for healthcare. The OECD recently launched Care Needed: Improving the Lives of People with Dementia, a report presenting the most up-to-date and comprehensive cross-country assessment of the state of dementia care in OECD countries. Elina was formerly based at SEEK Development in Berlin, where she worked with a range of organisations and international institutions on issues of health financing and global health governance. She graduated from McGill University and received her master’s degree from the Harvard School of Public Health.
Royal Melbourne Hospital, Australia
Professor Szoeke is the Director of the Women’s Healthy Ageing Project. She led the research program in Neurodegenerative Diseases, Mental Disorders and Brain Health at the Australian Commonwealth Science and Industry Organisation (CSIRO) and then became a Clinical Consultant to CSIRO.
She a practicing neurologist with an honours degree in Genetics and Pharmacology, MBBS and FRACP with specialisation in Neurology and subspecialisation in Epileptology. She completed her PhD thesis in Epidemiology examining women’s healthy ageing and her post doctoral studies conducted between Stanford University and the University of Melbourne focussed on cognition.
She has been in clinical research for over a decade with over 300 publications, is a reviewer for national and international journals.
LifeStory Health, USA
Anna Villarreal, J.D., is the CEO and Founder of LifeStory Health, Inc., (LSH) a bioscience company innovating precision medicine through diagnostic biomarkers. Over the last four years, Anna and her company’s novel scientific discovery has been recognized with various scientific and innovation awards, during which time Anna has become a known advocate for Women’s Health and Innovation. With features in dozens of publications, blogs and podcasts as well as scientific programs at Northeastern University as well as Baylor Scott and White Research Institute, Anna places a primary focus on how LSH and their partners are accelerating women’s healthcare. Anna is delighted to be a part of this Forum and looks forward to her further support of WBP’s mission.
Research and Policy Project Lead Alzheimer’s Disease International, UK
Wendy Weidner As Research and Policy Project Lead for Alzheimer’s Disease International (ADI), Wendy leads on ADI’s participation in the STRiDE (Strengthening responses to dementia in developing countries) project in partnership with the London School of Economics and Political Sciences (LSE) Personal Social Services Research Unit (PSSRU), universities and Alzheimer associations in seven countries in Asia, Africa, and the Americas. Her role also includes a focus on other research that ADI is involved in, including developing research webinars to provide a public interface between Alzheimer Associations and professionals providing dementia research in either biopsychosocial interventions or clinical trials. Wendy also works alongside ADI’s Medical and Scientific Advisory Panel. Before joining ADI, Wendy was the Business Development Manager for Dementia UK, where she led nationally on developing Admiral Nurse services, working closely with commissioners and other care providers to design new services that provided holistic and family-centred dementia care, while also providing social return on investment. Wendy also headed up a Dementia Pilot Project that looked at the impact of reminiscing with people with dementia. Wendy studied development economics and previously worked in project and service development and evaluation throughout Africa with the non-profit sector.
CEO, Inn Ventis Ltd, Israel
Dr. Thomas Wilckens is a medical doctor and a serial entrepreneur. He serves as the CEO of InnVentis Ltd., with a focus on the convergence of multi-omics technologies with real-world clinical data and machine learning to enable Precision Medicine. The InnVentis technology platform combines data of unprecedented quality and depth with cutting-edge algorithms to create actionable insights such as cost-efficient sourcing of extremely high quality *omics analytics and clinical analytics, proprietary knowledge in machine learning and algorithm development, and stringent control of sample and data collection
with proprietary standard operation procedures. Dr. Wilckens is also the founder of the LinkedIn group Precision Medicine Insight. Prior to InnVentis, he was an associate at deep innovation GmbH, a boutique consultancy and spin-off of Vodafone Group R&D Germany. In 1998 he founded a drug discovery company as CEO/CSO with a focus on inflammatory and metabolic diseases. Thomas obtained his MD at the Ludwig-Maximilian University in Munich and started his research career as a scholar of the Max-Planck Society and the Max-Kade Foundation in New York. He held several post-doctorate positions at leading academic institutions before becoming an entrepreneur.
Aside from his work in Precision Medicine he developed a novel concept for value creation in research intensive industries; i.e. “Symbiotic Innovation”. With regard to this project Thomas was an associate at the GLORAD Research Center for Global R&D Management St. Gallen/Shanghai. Thomas is convinced that we will see a disruption of current diagnostics & therapeutic concepts and related business models. This paradigm shift will be induced by the advent of even greater communication and computing capabilities in concert with progress in omics and sensor technologies; i.e. Precision Medicine will ultimately be supported by algorithms for prevention, diagnostics and therapeutic decision making and become available anywhere 24/7.